Restrepo S, Tabares A M, Restrepo A
Corporación de Investigaciones Biológicas (CIB), Hospital Pablo Tobón Uribe, Medellin, Colombia.
Rev Inst Med Trop Sao Paulo. 1992 Mar-Apr;34(2):171-6. doi: 10.1590/s0036-46651992000200014.
A new orally absorbable triazole (Schering 39304) with a long serum half-life in man (60 hours), was tried in a murine model of progressive paracoccidioidomycosis and compared with itraconazole, another triazole which has proven effective in this mycosis. Only 15% of the infected, untreated mice survived while 53 to 75% of the animals receiving itraconazole survived. Mice treated with Schering 39304 exhibited higher (86-100%) survival rates. Statistically, the 5 mg/kg Sch 39304 was superior to the 50 mg/kg itraconazole dose. Lung cultures showed that 20 mg/kg/day of Sch achieved sterilization of the infectious foci. These results indicate that the new triazole will have a place in the treatment of paracoccidioidomycosis.
一种新型口服可吸收三唑类药物（先灵葆雅39304）在人体中的血清半衰期较长（60小时），该药物在进行性副球孢子菌病的小鼠模型中进行了试验，并与另一种已被证明对这种真菌病有效的三唑类药物伊曲康唑进行了比较。未治疗的感染小鼠只有15%存活，而接受伊曲康唑治疗的动物有53%至75%存活。用先灵葆雅39304治疗的小鼠存活率更高（86% - 100%）。从统计学角度看，5mg/kg的Sch 39304优于50mg/kg的伊曲康唑剂量。肺部培养显示，20mg/kg/天的Sch 39304可实现感染病灶的杀菌。这些结果表明，这种新型三唑类药物在副球孢子菌病的治疗中将占有一席之地。
